ERBB2 and breast carcinoma: For the consideration of CBs in the therapy of breast cancer patients with difficult to treat HER2 expression tumors, a combination of CBs with HER2-targeted therapies, such as the tyrosine kinase inhibitor lapatinib, may be promising, as previous studies showed that CBs enhance the antitumor effects of the drugs.